-+ 0.00%
-+ 0.00%
-+ 0.00%

Exelixis wins Federal Circuit ruling upholding Cabometyx crystalline salt patents

PUBT·08/31/2026 18:30:42
Listen to the news
Exelixis wins Federal Circuit ruling upholding Cabometyx crystalline salt patents
  • Exelixis won a Federal Circuit appeal that upheld validity of three cabozantinib crystalline malate salt patents, supporting CABOMETYX exclusivity.
  • The court dismissed as moot the appeal over a low-impurity cabozantinib formulation patent, leaving the broader patent estate intact.
  • Earliest potential U.S. generic launch by MSN is January 15, 2030, subject to further appeals or regulatory exclusivity.
  • Generic timing also hinges on separate litigation over another low-impurity formulation patent expiring February 2032; trial set for November 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exelixis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260831878873) on August 31, 2026, and is solely responsible for the information contained therein.